-
Mashup Score: 0Study finds disparities in management of mCSPC - 10 hour(s) ago
“These findings suggest that guideline recommended treatment intensification remains low for patients with mCSPC in both Medicare and the Veterans Health Administration, but especially for Black patients,” says Daniel J. George, MD.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 5Addressing Unmet Needs and Final Perspectives on nmCRPC - 6 day(s) ago
Neal Shore, MD, FACS, concludes by addressing the remaining unmet needs in the management of non-metastatic castration-resistant prostate cancer.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
Neal Shore, MD, FACS, outlines his treatment approach, which favors single agents over combination therapies, and incorporates bone-health drugs, vitamins, nutrition guidance, and exercise recommendations to support patients. While PSA remains a valuable biomarker in prostate cancer, he notes that ctDNA and aspects of MRD are gaining importance, although not yet widely adopted.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0MRI Screening Detects Prostate Cancer Among Men With Germline Mutations - Renal and Urology News - 13 day(s) ago
Multiparametric MRI displayed 100% sensitivity and 100% negative predictive value in this high-risk population.
Source: www.renalandurologynews.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 0MRI + Blood Test Results May Cut Unnecessary Biopsies for Prostate Cancer - Renal and Urology News - 14 day(s) ago
Patient-tailored biopsy decisions still maintain high sensitivity
Source: www.renalandurologynews.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 1Overview of a 75-Year-old Patient with Non-Metastatic Castration-Resistant Prostate Cancer’s Case - 15 day(s) ago
Neal Shore, MD, FACS, reviews the case of a 75-year-old man with non-metastatic castration-resistant prostate cancer, seeks to evaluate the timeline of rising PSA to determine the aggressiveness of the disease, and considers the patient an excellent candidate for antigen receptor pathway inhibition.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Prostate Cancer Insights: Transformative Advancements in Care - 18 day(s) ago
In an interview with Targeted Oncology, Nasir Chaudry, MD, discussed the evolving landscape of prostate cancer treatment, driven by new research.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 4
Kim N. Chi, MD, FRCPC, discusses results from the MAGNITUDE trial, including those on survival and patient-reported outcomes in patients with BRCA-positive metastatic castration-resistant prostate cancer receiving niraparib plus abiraterone acetate and prednisone.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1MRI-Based Risk Calculators May Improve Patient Selection for Prostate Biopsy - Renal and Urology News - 28 day(s) ago
All models underpredicted the risk of clinically significant prostate cancer to some degree, supporting the use and future inclusion of advanced biomarkers.
Source: www.renalandurologynews.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 2Localized or Advanced Prostate Cancer Short- or Longer-Term Relugolix Plus Radiotherapy - The ASCO Post - 30 day(s) ago
In an analysis reported in JAMA Oncology, Daniel E. Spratt, MD, and colleagues found that treatment with relugolix was associated with rapid achievement of sustained castration in patients with localized or advanced prostate cancer who were also receiving radiotherapy. The analysis included patients from a phase II trial of relugolix vs degarelix and a subset of patients from the phase III HERO trial of relugolix vs leuprolide acetate, including 65 patients who received radiotherapy and short-term (24
Source: ascopost.comCategories: General Medicine News, Hem/OncsTweet
“These findings suggest that guideline recommended treatment intensification remains low for patients with mCSPC in both Medicare and the Veterans Health Administration, but especially for Black patients,” says Dr. @Daniel_J_George. @DukeUrology #pcsm https://t.co/5YHf17BGZp